https://ansm.sante.fr/tableau-acces-derogatoire/momelotinib 2024 false false false France French drug information N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
--- https://www.ema.europa.eu/en/medicines/human/EPAR/omjjara 2023 false false false Netherlands French English treatment outcome syndication feed summary of product characteristics package leaflet drug evaluation orphan drug production N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide momelotinib drug approval europe splenomegaly adult primary myelofibrosis risk management product surveillance, postmarketing Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase Post-Essential Thrombocythemia Myelofibrosis administration, oral pregnancy breast feeding drug interactions Janus Kinase Inhibitors Janus Kinase Inhibitors JAK1 Inhibitor JAK2 Inhibitor drug evaluation, preclinical
--- https://www.has-sante.fr/jcms/p_3478261/fr/omjjara-momelotinib-splenomegalie-et-symptomes-chez-les-patients-adultes-atteints-de-myelofibrose 2023 false false false France administration, oral anemia Secondary Myelofibrosis Janus Kinase Inhibitors momelotinib evaluation of the transparency committee splenomegaly adult N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Myelofibrosis